Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group

American Journal of Hematology

Volumn 90, Issue 4, 2015, Pages 282-287

  Iriyama, Noriyoshi ^a   Fujisawa, Shin ^b   Yoshida, Chikashi ^c   Wakita, Hisashi ^d   Chiba, Shigeru ^e   Okamoto, Shinichiro ^f   Kawakami, Kimihiro ^g   Takezako, Naoki ^h   Kumagai, Takashi ⁱ   Inokuchi, Koiti ^j   Ohyashiki, Kazuma ^k   Taguchi, Jun ^l   Yano, Shingo ^m   Igarashi, Tadahiko ⁿ   Kouzai, Yasuji ^o   Morita, Satoshi ^p   Sakamoto, Junichi ^q   Sakamaki, Hisashi ^r  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION MITO MEDICAL CENTER   (Japan)

^d NARITA RED CROSS HOSPITAL   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

^f KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION DISASTER MEDICAL CENTER   (Japan)

ⁱ Ohme Municipal General Hospital   (Japan)

^j NIPPON MEDICAL SCHOOL   (Japan)

^k TOKYO MEDICAL UNIVERSITY   (Japan)

^l SHIZUOKA RED CROSS HOSPITAL   (Japan)

^m JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ GUNMA PREFECTURAL CANCER CENTER   (Japan)

^o TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^p KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^q Tokai Central Hospital of Japan Mutual Aid Association of Public School Teachers   (Japan)

^r TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; RNA; ANTINEOPLASTIC AGENT; BCR-ABL1 FUSION PROTEIN, HUMAN; MESSENGER RNA; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC MYELOID LEUKEMIA; CHRONOTHERAPY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEUTROPENIA; NORMAL VALUE; OPEN STUDY; PLEURA EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RNA TRANSCRIPTION; SCORING SYSTEM; SOKAL SCORE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; BIOSYNTHESIS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETIC TRANSCRIPTION; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; MOLECULARLY TARGETED THERAPY; RECEIVER OPERATING CHARACTERISTIC; TIME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROSPECTIVE STUDIES; PYRIMIDINES; RNA, MESSENGER; RNA, NEOPLASM; ROC CURVE; THIAZOLES; TIME FACTORS; TRANSCRIPTION, GENETIC; YOUNG ADULT;

EID: 84925365783     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23923     Document Type: Article

References (24)

1. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
2. Kantarjian H, O'Brien S, Jabbour E, et al. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol 2011;29:3173-3178.
3. Tauchi T, Kizaki M, Okamoto S, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res 2011;35:585-590.
4. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.
5. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123-1129.
6. Fujisawa S, Nakamae H, Ogura M, et al. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up. Int J Hematol 2014;99:141-153.
7. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014;123:494-500.
8. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014;123:1353-1360.
9. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872-884.
10. Hanfstein B, Shlyakhto V, Lauseker M, et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 2014;28:1988-1992.
11. Branford S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 2014;124:511-518.
12. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol 2010;11:1029-1035.
13. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014;32:424-430.
14. Yoshida C, Fletcher L, Ohashi K, et al. Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan. Int J Clin Oncol 2012;17:584-589.
15. Kumagai T, Matsuki E, Inokuchi K, et al. Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. Int J Hematol 2014;99:41-52.
16. Ohnishi K, Nakaseko C, Takeuchi J, et al. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: The JALSG CML202 study. Cancer Sci 2012;103:1071-1078.
17. Inokuchi K, Kumagai T, Matsuki E, et al. Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase. J Clin Exp Hematop 2014;54:197-204.
18. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-1405.
19. Kim DH, Kamel-Reid S, Chang H, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for philadelphia chromosome positive leukemia. Haematologica 2009;94:135-139.
20. Nagata Y, Ohashi K, Fukuda S, et al. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol 2010;91:799-807.
21. Lee SJ, Jung CW, Kim DY, et al. Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia. Am J Hematol 2011;86:346-350.
22. Kreutzman A, Ladell K, Koechel C, et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011;25:1587-1597.
23. Linhares MI, de Andrade GP, Tateno S, et al. Prevalence of cytomegalovirus antibodies in Brazilian and Japanese populations in the north-east of Brazil. Microbiol Immunol 1989;33:975-980.
24. Furui Y, Satake M, Hoshi Y, et al. Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors. Transfusion 2013;53:2190-2197.